###begin article-title 0
###xml 86 87 86 87 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant
###end article-title 0
###begin p 1
###xml 157 158 157 158 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 452 453 452 453 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 612 613 612 613 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 210 213 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 237 241 <span type="species:ncbi:10090">mice</span>
Relative to several other toll-like receptor (TLR) agonists, we found polyinosinic:polycytidylic acid (poly IC) to be the most effective adjuvant for Th1 CD4+ T cell responses to a dendritic cell (DC)-targeted HIV gag protein vaccine in mice. To identify mechanisms for adjuvant action in the intact animal and the polyclonal T cell repertoire, we found poly IC to be the most effective inducer of type I interferon (IFN), which was produced by DEC-205+ DCs, monocytes, and stromal cells. Antibody blocking or deletion of type I IFN receptor showed that IFN was essential for DC maturation and development of CD4+ immunity. The IFN-AR receptor was directly required for DCs to respond to poly IC. STAT 1 was also essential, in keeping with the type I IFN requirement, but not type II IFN or IL-12 p40. Induction of type I IFN was mda5 dependent, but DCs additionally used TLR3. In bone marrow chimeras, radioresistant and, likely, nonhematopoietic cells were the main source of IFN, but mda5 was required in both marrow-derived and radioresistant host cells for adaptive responses. Therefore, the adjuvant action of poly IC requires a widespread innate type I IFN response that directly links antigen presentation by DCs to adaptive immunity.
###end p 1
###begin p 2
###xml 262 285 262 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib72">Seder and Mascola, 2003</xref>
###xml 358 376 358 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib81">Ulmer et al., 2006</xref>
###xml 670 695 670 695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib63">Pulendran and Ahmed, 2006</xref>
###xml 697 714 697 714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib33">Kool et al., 2008</xref>
###xml 185 188 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 921 928 <span type="species:ncbi:9606">patient</span>
Vaccines induce protective immunity against numerous infectious diseases. However, current vaccines have limited efficacy against challenging infections like tuberculosis, malaria, and HIV, where Th1-type T cell immunity likely has a potentially important role (Seder and Mascola, 2003). Proteins represent a potential route to safe new generation vaccines (Ulmer et al., 2006), but, typically, these are poorly immunogenic for T cells when administered alone. Therefore, special attention is being given to additional adjuvants or enhancers of immunity. Adjuvants activate innate immunity and, in particular, the maturation of antigen-presenting immunostimulatory DCs (Pulendran and Ahmed, 2006; Kool et al., 2008). To understand adjuvant action, and to identify optimal ones, it is necessary to move beyond the current focus on in vitro assays and selected monoclonal or TCR transgenic T cells to the intact animal and patient. This avenue of research should also help to identify mechanisms that link innate responses to adaptive immunity in vivo.
###end p 2
###begin p 3
###xml 147 165 147 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib2">Akira et al., 2006</xref>
###xml 167 188 167 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib30">Kawai and Akira, 2009</xref>
###xml 247 262 247 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib41">Li et al., 2008</xref>
###xml 717 740 717 740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib52">Mazzoni and Segal, 2004</xref>
###xml 742 761 742 761 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib36">Kwissa et al., 2007</xref>
###xml 882 900 882 900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib57">Nolte et al., 2007</xref>
Adjuvants can stimulate innate immunity by interacting with specialized pattern recognition receptors (PRRs), including Toll-like receptors (TLRs; Akira et al., 2006; Kawai and Akira, 2009) and nucleotide-binding oligomerization domain receptors (Li et al., 2008). DCs express a repertoire of PRR, allowing the recognition of a range of pathogen constituents. The engagement of PRR on DCs leads to de novo transcription and secretion of cytokines and chemokines, enhanced antigen presentation capacity, and migration to lymphoid tissues where the DCs interact with T cells and B cells to initiate and shape the adaptive immune response. The type of stimulus conditions DCs to adopt a Th1- or Th2-polarizing function (Mazzoni and Segal, 2004; Kwissa et al., 2007). However, many cell types, including nonhematopoietic cells, express PRR and produce cytokines during innate immunity (Nolte et al., 2007). To understand adjuvant action, it will likely be necessary to understand the contribution of cytokines and different cellular sources of cytokines to the initiation of immunity from the naive polyclonal repertoire.
###end p 3
###begin p 4
###xml 178 201 178 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib55">Nagano and Kojima, 1954</xref>
###xml 203 226 203 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib43">Lindenmann et al., 1957</xref>
###xml 352 371 352 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">Blanco et al., 2001</xref>
###xml 430 447 430 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib46">Luft et al., 1998</xref>
###xml 449 470 449 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib19">Gallucci et al., 1999</xref>
###xml 472 488 472 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib27">Ito et al., 2001</xref>
###xml 585 606 585 606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib60">Paquette et al., 1998</xref>
###xml 608 628 608 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib69">Santini et al., 2000</xref>
###xml 852 873 852 873 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib60">Paquette et al., 1998</xref>
###xml 875 895 875 895 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib61">Parlato et al., 2001</xref>
###xml 946 947 946 947 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 986 1005 986 1005 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib39">Le Bon et al., 2003</xref>
###xml 1008 1028 1008 1028 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib40">Le Bon et al. (2001)</xref>
###xml 505 510 <span type="species:ncbi:9606">human</span>
Among innate inflammatory cytokines, type I IFNs are considered to be major players for linking innate to adaptive immunity. First uncovered for their innate antiviral activity (Nagano and Kojima, 1954; Lindenmann et al., 1957), type I IFNs also enhance adaptive responses. They activate DCs, critical antigen-presenting cells for initiating immunity (Blanco et al., 2001), by promoting the expression of costimulatory molecules (Luft et al., 1998; Gallucci et al., 1999; Ito et al., 2001). This includes human blood monocytes, where type I IFN can stimulate differentiation into DCs (Paquette et al., 1998; Santini et al., 2000). Type I IFN-treated DCs prime T cells in vitro more effectively. The DCs also up-regulate expression of lymph node-homing CCR7 and exhibit stronger migratory capacity compared with DCs differentiated with other cytokines (Paquette et al., 1998; Parlato et al., 2001). Type I IFN further promotes cross-priming of CD8+ T cells by direct stimulation of DCs (Le Bon et al., 2003). Le Bon et al. (2001) showed that type I IFNs act on ex vivo-derived DCs to become better stimulators of antibody immunity. Nevertheless, the effects of type I IFN on DCs in situ need definition to understand the link between the innate production of cytokines to adaptive immunity.
###end p 4
###begin p 5
###xml 65 66 65 66 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 76 94 76 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib78">Tough et al., 1996</xref>
###xml 165 185 165 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib32">Kolumam et al., 2005</xref>
###xml 187 206 187 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib38">Le Bon et al., 2006</xref>
###xml 293 294 293 294 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 441 463 437 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib9">Brinkmann et al., 1993</xref>
###xml 465 484 461 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib85">Wenner et al., 1996</xref>
###xml 533 534 529 530 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 544 564 540 560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib48">Marrack et al., 1999</xref>
###xml 650 651 646 647 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 708 737 704 733 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib22">Havenar-Daughton et al., 2006</xref>
###xml 879 880 875 876 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1059 1080 1055 1076 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib5">Berenson et al., 2004</xref>
###xml 1082 1100 1078 1096 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib64">Ramos et al., 2007</xref>
###xml 1181 1182 1177 1178 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 860 865 <span type="species:ncbi:9606">human</span>
###xml 870 875 <span type="species:ncbi:10090">mouse</span>
Type I IFNs also have direct effects on T cells, particularly CD8+ T cells (Tough et al., 1996), by extending their survival during antigen-driven clonal expansion (Kolumam et al., 2005; Le Bon et al., 2006). In contrast, the importance of type I IFNs in the generation of antigen-specific CD4+ T cell responses is uncertain. Type I IFN inhibits secretion of Th2 cytokines (IL-4 and IL-5) and stimulates type II IFN or IFN-gamma production (Brinkmann et al., 1993; Wenner et al., 1996). Type I IFNs inhibit the death of activated CD4+ T cells (Marrack et al., 1999), a finding which was later extended to the adoptive transfer of antigen-specific CD4+ T cells lacking the expression of type I IFN receptors (Havenar-Daughton et al., 2006). However, although it was originally believed to induce STAT4 activation, type I IFN failed to promote Th1 commitment in human and mouse CD4+ T cells in vitro. Despite induction of detectable STAT4 tyrosine phosphorylation, the activation was transient and insufficient to drive Th1 development in the absence of IL-12 (Berenson et al., 2004; Ramos et al., 2007). Therefore, the effect of type I IFNs on the generation of antigen-specific CD4+ T cells in vivo is unclear from these observations.
###end p 5
###begin p 6
###xml 230 248 230 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib68">Salem et al., 2006</xref>
###xml 250 275 250 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib80">Trumpfheller et al., 2008</xref>
###xml 277 302 277 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib75">Stahl-Hennig et al., 2009</xref>
###xml 559 576 559 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib29">Kato et al., 2006</xref>
###xml 799 823 799 823 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib3">Alexopoulou et al., 2001</xref>
###xml 825 844 825 844 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib21">Gitlin et al., 2006</xref>
Several TLR agonists are currently being evaluated as adjuvants for vaccine development. Among them, synthetic double-stranded RNA, polyinosinic:polycytidylic acid (poly IC), induces inflammation and long-lasting T cell immunity (Salem et al., 2006; Trumpfheller et al., 2008; Stahl-Hennig et al., 2009). Poly IC is recognized by TLR3 located mostly in endosomal membranes. Also, poly IC binds the cytoplasmic RNA helicase MDA5, resulting in activation of IRF-3 and representing a major pathway for the production of type I IFNs in a TLR-independent fashion (Kato et al., 2006). Poly IC is a strong inducer of type I IFN. Although DCs and macrophages produce type I IFN upon poly IC stimulation in vitro, many nonhematopoietic cell types potentially could provide a source of this cytokine in vivo (Alexopoulou et al., 2001; Gitlin et al., 2006). In addition, the critical question of whether type I IFN is required for the adjuvant effect of poly IC and its mechanism of action in situ has not been addressed.
###end p 6
###begin p 7
###xml 67 68 67 68 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 212 237 212 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib80">Trumpfheller et al., 2008</xref>
###xml 648 649 648 649 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 865 866 865 866 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 89 92 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
In this paper, we study the mechanism whereby poly IC adjuvants CD4+ Th1 immunity for an HIV gag protein vaccine that is targeted in vivo to DCs within a monoclonal antibody to the uptake receptor DEC-205/CD205 (Trumpfheller et al., 2008). We found that poly IC is a superior adjuvant and then we made several findings on its effects in vivo. First, type I IFN is the dominant driver of two innate cellular responses: the maturation of DCs and the activation of NK cells to produce type II IFN. Second, type I IFN must act directly on DCs to induce their maturation into immunostimulatory cells and also is necessary for the generation of a Th1 CD4+ adaptive T cell response, whereas IL-12 and type II IFN-R are not. Third, both bone marrow-derived and stromal cells play essential roles in providing type I IFN. These data illustrate that poly IC adjuvants Th1 CD4+ T cell immunity by replicating the early systemic effects of viral infection through its superior and widespread induction of type I IFN.
###end p 7
###begin title 8
RESULTS
###end title 8
###begin title 9
###xml 38 39 38 39 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Poly IC is a superior adjuvant for CD4+ T cell responses to a protein vaccine
###end title 9
###begin p 10
###xml 121 122 121 122 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 194 219 194 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib80">Trumpfheller et al., 2008</xref>
###xml 494 495 494 495 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">l</sc>
###xml 143 146 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 650 654 <span type="species:ncbi:10090">Mice</span>
We had previously shown that poly IC was a superior adjuvant to monophosphoryl lipid A for inducing strong protective CD4+ T cell responses to HIV gag p24 delivered within an anti-DEC antibody (Trumpfheller et al., 2008). To find the most appropriate adjuvant for this new approach to protein-based vaccines, we extended our analysis to other TLR ligands, including MALP-2 (TLR2/TLR6), Pam3Cys (TLR1/TLR2), poly IC (TLR3), poly ICLC (TLR3-complexed poly IC with carboxymethylcellulose and poly-l-lysine to improve resistance to ribonucleases), LPS (TLR4), R-848 (TLR7/TLR8) delivered as an aqueous compound or within a topical cream, and CpG (TLR9). Mice were immunized with alpha-DEC-gag p24 mAb and specific adjuvants twice i.p. over 4 wk. 1 wk after the final injection, antigen-specific responses were evaluated by IFN-gamma secretion in response to gag p24 peptides, primarily by multicolor flow cytometry.
###end p 10
###begin p 11
###xml 80 81 80 81 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 134 149 134 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1, A and B</xref>
###xml 201 202 197 198 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 205 206 201 202 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 253 254 249 250 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 527 535 519 527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 C</xref>
###xml 647 662 639 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1, A and B</xref>
###xml 845 853 837 845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 D</xref>
###xml 1020 1021 1012 1013 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 745 748 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Poly IC, together with its analogue poly ICLC, induced stronger gag-specific CD4+ T cell responses compared with the other adjuvants (Fig. 1, A and B) with frequencies of >1% of IFN-gamma producing CD3+CD4+ T cells after i.p. injection. The improved CD4+ T cell responses with poly IC and poly ICLC were also evident at the single cell level when IL-2 and TNF-alpha were measured (). ELISA assays showed that IL-4 and IL-17 were not induced during the adjuvant role of poly IC or poly ICLC, verifying a polarized Th1 response (Fig. 1 C). The second most active adjuvant was R-848 applied in a cream to the skin, but the other adjuvants were weak (Fig. 1, A and B). To verify the activity of the adjuvants, we also measured antibody responses to HIV gag and found that all the adjuvants were active, with LPS being at least as active as poly IC (Fig. 1 D). These results encouraged us to compare the innate response to poly IC relative to other agonists to help explain its superior adjuvant role in inducing Th1 type CD4+ T cell immunity.
###end p 11
###begin p 12
###xml 44 45 44 45 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 0 62 0 62 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Poly IC is a superior adjuvant to elicit CD4<sup>+</sup> T cell immunity.</bold>
###xml 73 74 73 74 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 313 314 281 282 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 375 376 339 340 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 379 380 343 344 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 635 636 597 598 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 75 79 <span type="species:ncbi:10090">mice</span>
###xml 337 341 <span type="species:ncbi:10090">mice</span>
###xml 412 415 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 609 613 <span type="species:ncbi:10090">mice</span>
###xml 637 641 <span type="species:ncbi:10090">mice</span>
###xml 1067 1071 <span type="species:ncbi:10090">mice</span>
###xml 1084 1088 <span type="species:ncbi:10090">Mice</span>
###xml 1268 1272 <span type="species:ncbi:10090">mice</span>
Poly IC is a superior adjuvant to elicit CD4+ T cell immunity. (A) CxB6 F1 mice were primed and boosted 4 wk apart with 5 microg alpha-DEC-p24 and 50 microg poly IC, 50 microg Pam3cys, 0.5 microg Malp2, 50 microg poly ICLC, 10 microg LPS, 50 microg CpG, or R-848 cream. R-848 cream was applied topically over 5 cm2 on the back of shaved mice. IFN-gamma secretion in gated CD3+CD4+ splenic T cells in response to HIV gag p24 peptides was measured 1 wk after boost. (B) As in A, but means +/- SD from five (poly IC), three (poly ICLC, R-848, and CpG), and two (Malp-2, Pam3cys, and LPS) experiments, with three mice per group. (C) CxB6 F1 mice were primed and boosted 4 wk apart with 5 microg alpha-DEC-p24 and 50 microg poly IC. 1 wk after boost, bulk splenocytes were stimulated with gag p24 peptide mix or control peptide mix for 3 d. The concentrations of the indicated cytokines and chemokines were measured in cell culture supernatants by luminex. Samples were acquired in duplicate and analyzed by ELISA. Bars represent the mean +/- SD from two experiments (six mice total). (D) Mice were immunized as in A. 1 wk after boost, gag-specific antibodies in serum samples were measured by ELISA. Data are given as OD mean +/- SD from two independent experiments (five mice total).
###end p 12
###begin title 13
The innate response to poly IC uniquely leads to high levels of serum type I IFN
###end title 13
###begin p 14
###xml 425 431 406 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2</xref>
###xml 765 771 736 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2</xref>
To assess the innate response to poly IC and poly ICLC, we studied the systemic release of inflammatory cytokines, a prototype response to agonists for PRR. We did ELISA assays on serum at 1, 3, 6, or 20 h after administration of different TLR ligands i.p., measuring IL-6, TNF-alpha, IL-12p40, IFN-gamma, IFN-alpha, and IFN-beta. All TLR agonists, to different extents, induced production of IL-6, TNF-alpha, and IL-12 p40 (Fig. 2), whereas serum IL-12p70, IL-1beta, and IL-10 were not detected (not depicted). Interestingly, production of type I and type II IFNs was more restricted, being detected primarily with poly IC, poly ICLC, and R-848. Detection of IFN-alpha and IFN-beta was transient, peaking at 3-6 h, and was highest with both poly IC and poly ICLC (Fig. 2). Thus, strong type I IFN production is a special feature of poly IC, suggesting a role for IFN in its adjuvant effect.
###end p 14
###begin p 15
###xml 0 64 0 64 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Induction of inflammatory cytokines in the serum by TLR ligands.</bold>
###xml 208 209 184 185 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 65 69 <span type="species:ncbi:10090">Mice</span>
###xml 356 360 <span type="species:ncbi:10090">mice</span>
Induction of inflammatory cytokines in the serum by TLR ligands. Mice were treated i.p. with 50 microg poly IC, 50 microg Pam3cys, 0.5 microg Malp2, 10 microg LPS, 50 microg poly ICLC, 50 microg CpG, and 5 cm2 of 0.2% R-848 cream. IL-6, TNF-alpha, IL-12p40, IFN-alpha, IFN-beta, and IFN-gamma were analyzed in serum at different time points (means of four mice). Error bars indicate the mean +/- SD. Data are representative of two similar independent experiments.
###end p 15
###begin title 16
Poly IC induces activation of DCs
###end title 16
###begin p 17
###xml 42 62 42 62 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib82">Verdijk et al., 1999</xref>
###xml 64 83 64 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">Blanco et al., 2001</xref>
###xml 85 103 85 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib44">Lopez et al., 2004</xref>
###xml 105 120 105 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib88">Tsujimoto, 2006</xref>
###xml 178 196 178 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib25">Honda et al., 2003</xref>
###xml 546 547 535 536 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 555 556 544 545 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 593 601 582 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 A</xref>
###xml 21 26 <span type="species:ncbi:10090">mouse</span>
###xml 31 36 <span type="species:ncbi:9606">human</span>
###xml 284 288 <span type="species:ncbi:10090">mice</span>
Poly IC matures both mouse and human DCs (Verdijk et al., 1999; Blanco et al., 2001; Lopez et al., 2004; Tsujimoto, 2006), and this maturation was shown to depend on type I IFN (Honda et al., 2003). However, these experiments were performed in vitro. To assess DC maturation in vivo, mice were injected with 50 microg poly IC, and the effect of type I IFN was blocked by simultaneous injection of IFNAR1 (anti-IFN-alphabeta receptor) antibody or isotype control. After 12 h, expression of MHC-II and costimulatory molecules (CD40 and CD86) on DEC+ and DEC- DCs was analyzed by flow cytometry (Fig. 3 A). Blocking type I IFN receptor effectively reduced DC maturation, as monitored by the up-regulation of these immunostimulatory molecules in response to poly IC.
###end p 17
###begin p 18
###xml 0 44 0 44 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Type I IFN signaling controls DC maturation.</bold>
###xml 234 235 226 227 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 243 244 235 236 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 348 349 340 341 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 435 436 427 428 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 122 126 <span type="species:ncbi:10090">mice</span>
###xml 315 319 <span type="species:ncbi:10090">mice</span>
Type I IFN signaling controls DC maturation. (A) 1 h after 100 microg of anti-IFAR1 blocking antibody or isotype control, mice were stimulated with 50 microg poly IC for 12 h and analyzed for cell surface MHC-II, CD86, and CD40 on DEC+ and DEC- DCs. (B) As in A, but graded numbers of fixed splenic DCs from BALB/C mice were added for 5 d to 2 x 105 allogeneic C57BL/6 T cells. T cell proliferation was detected by CFSE dilution of CD3+ cells. Data are representative of three experiments.
###end p 18
###begin p 19
###xml 150 151 150 151 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 461 469 461 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 B</xref>
###xml 352 356 <span type="species:ncbi:10090">mice</span>
To directly evaluate the stimulatory capacity of DCs after poly IC stimulation with or without blockade of type I IFN receptors, we isolated the CD11c+ DC fraction from the spleen, fixed the cells with formaldehyde to block further differentiation in culture, and added the DCs in graded doses to allogeneic T cells in an MLR. DCs from poly IC-treated mice became active stimulators of the allogeneic MLR, whereas blockade of type I IFNs abrogated this effect (Fig. 3 B), showing that this cytokine was essential for DC maturation in response to the poly IC adjuvant.
###end p 19
###begin title 20
Direct IFNAR signaling is critical for DC activation in vivo
###end title 20
###begin p 21
###xml 211 214 211 214 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 222 230 222 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 A</xref>
###xml 372 380 372 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 B</xref>
###xml 429 437 429 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 C</xref>
###xml 274 278 <span type="species:ncbi:10090">mice</span>
To determine if type I IFN had to act directly on DCs to bring about maturation, we made mixed bone marrow chimeras in which the injected bone marrow suspension was a 50:50 mixture of CD45.1 WT and CD45.2 IFN-AR-/- cells (Fig. 4 A). When poly IC was given to these chimeric mice, only the CD45.1 WT cells were able to up-regulate costimulatory molecules and MHC class II (Fig. 4 B) and exhibit enhanced MLR stimulatory activity (Fig. 4 C and ). Therefore, Type I IFN directly promotes maturation of DCs to link innate to adaptive immunity.
###end p 21
###begin p 22
###xml 0 68 0 68 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Direct type I IFN signaling of DCs is required for their maturation.</bold>
###xml 161 162 161 162 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 173 176 173 176 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 184 185 184 185 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 227 228 227 228 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 239 242 239 242 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 250 251 250 251 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 406 409 402 405 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 508 511 504 507 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 595 598 591 594 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 604 606 600 602 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hi</sup>
###xml 674 677 670 673 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 718 719 714 715 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 804 805 800 801 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 846 847 842 843 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 187 191 <span type="species:ncbi:10090">mice</span>
Direct type I IFN signaling of DCs is required for their maturation. Mixed bone marrow chimeras were prepared with a 50:50 mixture of bone marrow from WT (CD45.2-) and IFNAR-/- (CD45.2+) mice. (A) Gating strategy for WT (CD45.2-) and IFNAR-/- (CD45.2+) DCs 4-6 wk after chimerism. (B) The chimeras were stimulated with 50 microg poly IC or PBS for 12 h. Expression of CD86, MHC-II, and CD40 on WT and IFNAR-/- DCs, was analyzed by FACS. Arrows show increased up-regulation of costimulatory molecules in IFNAR-/- DCs. (C) The chimeras were stimulated as in B. After CD11c enrichment, WT and IFNAR-/- CD11chi were FACS sorted as in A. Graded numbers of fixed B6.WT or B6.IFNAR-/- splenic DCs were added for 5 d to 2 x 105 allogeneic Balb/C T cells. T cell proliferation was detected by CFSE dilution of CD3+ cells. Cells numbers are indicated as 103. Data are representative of two similar independent experiments.
###end p 22
###begin title 23
Poly IC induces IFN-gamma production by NK cells
###end title 23
###begin p 24
###xml 146 164 142 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib68">Salem et al., 2006</xref>
###xml 294 297 286 289 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">int</sup>
###xml 300 301 292 293 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 382 386 370 374 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 389 390 377 378 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 410 425 398 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5, A and B</xref>
An additional component to the innate response to the in vivo administration of poly IC is the rapid activation of NK cells to produce IFN-gamma (Salem et al., 2006). Because we had observed an innate IFN-gamma response to poly IC, we assessed NK cells as a possible source. We found that CD11cintDX5+ NK cells were major producers of IFN-gamma, whereas other cells, including CD11chighDX5- DCs were inactive (Fig. 5, A and B).
###end p 24
###begin p 25
###xml 0 56 0 52 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NK cells are major producers of IFN-&#947; after poly IC.</bold>
###xml 418 419 394 395 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 423 424 399 400 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 489 490 463 464 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 494 495 468 469 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 512 513 486 487 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 57 61 <span type="species:ncbi:10090">Mice</span>
###xml 760 764 <span type="species:ncbi:10090">Mice</span>
NK cells are major producers of IFN-gamma after poly IC. Mice were injected i.p. with 50 microg poly-IC or PBS. After 2 h, spleens were collected and a single cell suspension of splenocytes was incubated with 10 microg/ml BFA for 3 h before intracellular staining for IFN-gamma. (A) Five color flow cytometry to identify IFN-gamma-positive splenocytes. (B) As in A, but production of IFN-gamma by NK cells gated as CD3- DX5+ cells. Means +/- SD of four experiments. (C) Highly purified CD3- DX5+ NK cells. 3 x 105 cells/well were stimulated with 50 microg/ml poly IC or, as a positive control, a combination of rIL-12 and rIL-15. After 12 h, IFN-gamma in culture supernatants was detected by ELISA. Means +/- SD of three independent experiments are shown. (D) Mice were injected with poly IC and anti-IFAR1 blocking antibody or isotype control. Production of IFN-gamma was detected by intracellular staining. Mean +/- SD from three experiments is shown.
###end p 25
###begin p 26
###xml 73 92 69 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib37">Lauzon et al., 2006</xref>
###xml 219 238 215 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib70">Sawaki et al., 2007</xref>
###xml 485 504 477 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib84">Walzer et al., 2005</xref>
###xml 597 605 589 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 C</xref>
###xml 878 886 866 874 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 D</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 121 126 <span type="species:ncbi:10090">mouse</span>
###xml 581 586 <span type="species:ncbi:10090">mouse</span>
###xml 717 721 <span type="species:ncbi:10090">mice</span>
Human NK cells respond directly to poly IC and CpG to produce IFN-gamma (Lauzon et al., 2006) but, in contrast, purified mouse NK cells fail to respond directly to TLR agonists and require the presence of DCs or IL-12 (Sawaki et al., 2007). To assess the latter possibility, highly purified splenic NK cells were incubated overnight in the presence of poly IC, and IFN-gamma production was measured by ELISA. As a positive control, the NK cells were stimulated with rIL-12 and rIL-15 (Walzer et al., 2005). In concordance with previous studies, poly IC failed to directly activate mouse NK cells (Fig. 5 C). We then considered that NK activation was indirect and a result of stimulation by type I IFNs. To test this, mice were injected with poly IC 1 h after injection of anti-IFNAR1 or isotype control. Antibody treatment dramatically reduced IFN-gamma production by NK cells (Fig. 5 D). Collectively, these results highlight the importance of type I IFN during the innate responses of both DCs and NK cells in the intact animal.
###end p 26
###begin title 27
Poly IC directly activates multiple cell types to produce type I IFN
###end title 27
###begin p 28
###xml 240 259 240 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib21">Gitlin et al., 2006</xref>
###xml 261 281 261 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib35">Kumagai et al., 2007</xref>
###xml 661 662 661 662 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 665 666 665 666 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 702 705 702 705 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">int</sup>
###xml 708 709 708 709 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 713 714 713 714 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 735 737 735 737 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hi</sup>
###xml 740 741 740 741 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 744 745 744 745 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 752 753 752 753 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 760 761 760 761 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 763 771 763 771 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6 A</xref>
###xml 773 801 773 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib4">Asselin-Paturel et al., 2005</xref>
###xml 803 823 803 823 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib7">Blasius et al., 2007</xref>
###xml 825 845 825 845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib14">Dudziak et al., 2007</xref>
###xml 902 904 902 904 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hi</sup>
###xml 933 935 933 935 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hi</sup>
###xml 958 959 958 959 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1004 1007 1004 1007 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">low</sup>
###xml 1012 1013 1012 1013 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1021 1029 1021 1029 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6 A</xref>
###xml 1031 1050 1031 1050 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib76">Taylor et al., 2005</xref>
###xml 1052 1073 1052 1073 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib65">Randolph et al., 2008</xref>
###xml 145 150 <span type="species:ncbi:10090">mouse</span>
Type I IFNs are rapidly produced by many cell types in response to immune and/or inflammatory stimuli. Poly IC was previously shown to stimulate mouse conventional DCs (cDCs), bone morrow-derived DCs, and macrophages to produce type I IFN (Gitlin et al., 2006; Kumagai et al., 2007). Splenic cells were sorted into several different cell types, stimulated in vitro with poly IC, and tested for the production of type I IFN. First, spleen cells were preenriched by magnetic depletion of B, T, and erythroid cells with antibodies to CD19, CD3, and TER119. The depleted cells were then sorted based on the expression of a set of specific markers. NK cells were CD3-DX5+, plasmacytoid DCs (pDCs) were CD11cintDX5-B220+, and cDCs were CD11chiDX5-CD8- or CD8+DEC-205+ (Fig. 6 A; Asselin-Paturel et al., 2005; Blasius et al., 2007; Dudziak et al., 2007). To sort granulocytes and monocytes, we gated for CD11bhi cells and then isolated LyC6hi granulocytes and CD115+ monocytes. Macrophages were defined as CD11blowF4/80+ cells (Fig. 6 A; Taylor et al., 2005; Randolph et al., 2008).
###end p 28
###begin p 29
###xml 0 46 0 43 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Production of IFN-&#946; by multiple cell types.</bold>
###xml 101 102 98 99 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 107 108 104 105 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 118 119 115 116 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 290 291 287 288 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 308 309 305 306 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 312 313 309 310 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 318 320 315 317 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hi</sup>
###xml 323 324 320 321 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 332 333 329 330 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 339 340 336 337 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 352 353 349 350 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 356 357 353 354 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 362 365 359 362 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">low</sup>
###xml 369 370 366 367 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 386 387 383 384 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 390 391 387 388 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 412 415 409 412 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">low</sup>
###xml 420 421 417 418 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 440 442 437 439 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hi</sup>
###xml 447 448 444 445 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 474 476 471 473 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hi</sup>
###xml 480 481 477 478 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 654 655 651 652 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 854 855 847 848 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 994 995 987 988 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1039 1040 1032 1033 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1149 1152 1138 1141 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1234 1237 1223 1226 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 71 75 <span type="species:ncbi:10090">mice</span>
###xml 1061 1065 <span type="species:ncbi:10090">mice</span>
###xml 1153 1157 <span type="species:ncbi:10090">mice</span>
###xml 1238 1242 <span type="species:ncbi:10090">mice</span>
Production of IFN-beta by multiple cell types. (A) Splenocytes from WT mice were depleted with Ter119-, CD3-, and CD19- biotinylated antibodies using streptavidin magnetic beads before cell sorting. For monocytes, macrophages, and granulocytes, splenocytes were additionally depleted of DX5+ cells. cDCs (CD3-DX5-CD11chiCD8- and CD8+DEC205+), pDCs (CD3-DX5-CD11clowB220+), NK cells (CD3-DX5+), macrophages (CD11blowF4/80+), monocytes (CD11bhiCD115+), and granulocytes (CD11bhiLy6G+) were sorted based on their expression of specific markers (see text). Numbers 1-6 indicate the different cell types sorted. (B) Highly purified cells were plated at 3 x 105 cells/well in a round-bottomed 96-well plate and incubated with 50 microg/ml poly IC or medium alone. Splenic stromal cells, obtained as described in the Materials and methods, were plated at 5 x 104 cells/well in a 48-well plate. Supernatants were collected after 12 h and production of Type I IFN was detected by ELISA. (C) As in B, DEC+ DCs, monocytes, stromal cells from WT, TLR3-, and mda5-deficient mice were stimulated in vitro with 50 microg/ml poly IC or medium alone. (D) WT and mda5-/- mice were lethally irradiated and injected with bone marrow cells from WT or mda5-/- mice. After 6 wk, chimeras were injected with 50 microg poly IC. Serum was collected 6 h later and analyzed by Type I IFN ELISA kit. Error bars show the means +/- SD from at least two experiments. ND, not detectable.
###end p 29
###begin p 30
###xml 44 45 44 45 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 106 107 106 107 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 110 111 110 111 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 162 163 162 163 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 218 226 218 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6 B</xref>
###xml 330 331 327 328 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 428 429 425 426 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 482 490 479 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6 B</xref>
When each of the sorted cell subsets (3 x 105 cells/well) were stimulated overnight with poly IC, both CD8+DEC+ DCs and monocytes produced type I IFN, whereas CD8- DCs, pDCs, NK, granulocytes, and macrophages did not (Fig. 6 B). To test the capacity of nonhematopoietic cells to produce IFN-beta, we used splenic stromal cells (105 cells/well) that had been expanded from CD45-negative spleen cells. Similar to monocytes and DEC+ DCs, stromal cells were able to produce type I IFN (Fig. 6 B).
###end p 30
###begin p 31
###xml 210 227 210 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib28">Kato et al., 2005</xref>
###xml 366 367 363 364 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 403 406 400 403 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 415 418 412 415 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 596 599 590 593 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 647 650 641 644 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 658 666 652 660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6 C</xref>
###xml 860 879 854 873 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib21">Gitlin et al., 2006</xref>
###xml 885 886 879 880 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 975 983 966 974 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6 C</xref>
###xml 419 423 <span type="species:ncbi:10090">mice</span>
###xml 760 764 <span type="species:ncbi:10090">mice</span>
###xml 1010 1014 <span type="species:ncbi:10090">mice</span>
Although production of type I IFN by pDCs requires activation of the TLR system, cDCs and fibroblasts were shown to secrete type I IFNs in response to viral infection in a cytosolic helicase-dependent fashion (Kato et al., 2005). Because poly IC can be recognized by the RNA helicase mda5, we next tested if poly IC-induced IFN-beta required this PRR. Monocytes, DEC+ DC, and stromal cells from WT, mda5-/-, or TLR3-/- mice were stimulated in vitro with poly IC as described in the previous paragraph. Interestingly, the production of IFN-beta by all cell types was comparable between WT and TLR3-/- cells, whereas it was severely impaired in mda5-/- cells (Fig. 6 C). Similar results were obtained when we measured the release of type I IFN into the serum of mice genetically deficient in these PRRs after poly IC injection (), confirming prior observations (Gitlin et al., 2006). DEC+ DCs were also able to produce small amounts of IFN-beta in an mda5-independent fashion (Fig. 6 C), but this was ablated in mice doubly deficient in TLR3 and mda5 (not depicted).
###end p 31
###begin p 32
###xml 93 94 93 94 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 226 229 226 229 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 310 313 310 313 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 448 451 448 451 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 511 514 504 507 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 566 574 559 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6 D</xref>
###xml 230 234 <span type="species:ncbi:10090">mice</span>
###xml 277 281 <span type="species:ncbi:10090">mice</span>
To investigate the extent to which type I IFN in vivo required hematopoietic cells, e.g., DEC+ DCs and monocytes, and nonhematopoietic cells, e.g., endothelia, stromal bone marrow chimeras were generated by reconstituting mda5-/- mice with WT bone marrow or, alternatively, WT mice were reconstituted with mda5-/- marrow. The different chimeras were injected i.p with poly IC, and serum was collected after 6 h. Interestingly, WT recipients of mda5-/- marrow produced high levels of IFN-alpha/beta, whereas mda5-/- recipients of WT marrow were severely compromised (Fig. 6 D). These data demonstrated that stimulation of radioresistant cells, but not bone marrow-derived cells, was required for the bulk of type I IFN production after poly IC treatment.
###end p 32
###begin title 33
Production of type I IFNs by poly IC, but not IL-12 p40, is needed for Th1 immunity
###end title 33
###begin p 34
###xml 119 120 119 120 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 354 362 350 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7 A</xref>
###xml 495 498 487 490 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 599 607 587 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7 B</xref>
###xml 862 865 846 849 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 872 880 856 864 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7 C</xref>
###xml 164 168 <span type="species:ncbi:10090">mice</span>
###xml 499 503 <span type="species:ncbi:10090">mice</span>
###xml 680 684 <span type="species:ncbi:10090">mice</span>
###xml 866 870 <span type="species:ncbi:10090">mice</span>
To determine if type I IFN could influence the development of adaptive Th1 immunity, we first analyzed gag-specific CD4+ T cells responses after IFNAR1 blocking of mice immunized with either alpha-DEC-p24 or nontargeted gag p41 protein. In both cases, the adjuvant effect of poly IC was markedly reduced by IFNAR1 blocking compared with isotype control (Fig. 7 A and ). TNF-alpha and IL-2 production likewise was also severely reduced (unpublished data). Similar results were obtained with IFNAR-/- mice, which were unable to develop adaptive Th1 immunity in response to alpha-DEC-p24 plus poly IC (Fig. 7 B). To extend the evidence for a critical role of type I IFNs, we studied mice with a genetic deletion of STAT1, the major signal transducer for type I IFNs. As anticipated, immunization with either alpha-DEC-p24 or p41 protein was totally ablated in STAT1-/- mice (Fig. 7 C and Fig. S4 B). Thus, the stimulation of type I IFNs by poly IC is required for its adjuvant role.
###end p 34
###begin p 35
###xml 0 86 0 86 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">The adjuvant role of poly IC is dependent on type I IFNs and independent of IL-12 p40.</bold>
###xml 97 98 97 98 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 324 325 308 309 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 329 330 313 314 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 412 413 392 393 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 417 418 397 398 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 472 475 448 451 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 483 486 459 462 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 498 501 470 473 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 516 519 488 491 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 99 103 <span type="species:ncbi:10090">mice</span>
###xml 240 244 <span type="species:ncbi:10090">Mice</span>
###xml 304 307 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 530 534 <span type="species:ncbi:10090">mice</span>
###xml 624 628 <span type="species:ncbi:10090">mice</span>
The adjuvant role of poly IC is dependent on type I IFNs and independent of IL-12 p40. (A) CxB6 F1 mice were injected i.p. with 5 microg alpha-DEC-p24 or 10 microg gag-p41 and 50 microg poly IC together with anti-IFNAR1 or isotype control. Mice were boosted with the same conditions at 4 wk. 1 wk later, HIV gag-specific CD3+ CD4+ splenic T cells were analyzed for IFN-gamma. (B-E) As in A, the percentage of CD3+ CD4+ T cells producing IFN-gamma was measured in WT, IFNAR-/-, STAT-1-/-, IFN-gammaR-/-, and IL-12 p40-/- immunized mice, respectively. Means +/- SD are shown of two independent experiments with a total of six mice. ***, P = 0.001.
###end p 35
###begin p 36
###xml 192 211 181 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib85">Wenner et al., 1996</xref>
###xml 213 233 202 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib54">Montoya et al., 2002</xref>
###xml 309 310 295 296 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 394 412 380 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib67">Rogge et al., 1997</xref>
###xml 519 520 501 502 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 655 658 625 628 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 671 674 641 644 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 718 733 688 703 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7, D and E</xref>
###xml 300 305 <span type="species:ncbi:9606">human</span>
###xml 634 638 <span type="species:ncbi:10090">mice</span>
###xml 675 679 <span type="species:ncbi:10090">mice</span>
###xml 712 716 <span type="species:ncbi:10090">mice</span>
Type I IFNs may regulate Th1 responses by indirect mechanisms. IFN-alphabeta signaling can up-regulate IFN-gamma production by DCs, promoting the ability of naive T cells to respond to IL-12 (Wenner et al., 1996; Montoya et al., 2002), whereas type I IFN can up-regulate expression of IL-12Rbeta2 on human CD4+ T cells, increasing responsiveness to IL-12, a pivotal cytokine for Th1 responses (Rogge et al., 1997). To determine if type I IFN might additionally require either increased IFN-gamma or IL-12 signaling, CD4+ T cell responses to DEC-p24 and poly IC were analyzed in IFN-gammaR (IFN-gamma receptor) and IL-12 p40-deficient mice. Both IFN-gammaR-/- and IL-12p40-/- mice mounted similar responses to WT mice (Fig. 7, D and E and Fig. S4, C and D), implying that type I IFN, but not type II IFN or IL-12, was directly required for poly IC to induce polarized Th1 immunity.
###end p 36
###begin title 37
IFN from both bone marrow-derived and nonhematopoietic cells is needed for the adjuvant function of poly IC
###end title 37
###begin p 38
###xml 148 149 148 149 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 168 193 168 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib80">Trumpfheller et al., 2008</xref>
###xml 592 598 592 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig8">Fig. 8</xref>
###xml 217 221 <span type="species:ncbi:10090">mice</span>
###xml 333 337 <span type="species:ncbi:10090">mice</span>
Because mda5 and TLR3 are the major PRRs for type I IFN production in response to poly IC, and both receptors were needed to induce gag-specific CD4+ T cell responses (Trumpfheller et al., 2008), we analyzed chimeric mice in which either the bone marrow donor or recipient were lacking both mda5 and TLR3. The B and T cells in these mice were >98% donor in origin after typing with anti-CD45.1 and anti-CD45.2 (unpublished data). In each case, i.e., when either the hematopoietic cells or nonhematopoietic cells could not make type I IFN via poly IC, its adjuvant effect was reduced by >80% (Fig. 8). These results indicate that a systemic innate response, and not only a local response by antigen-capturing DCs, accounts for the adjuvant role of poly IC.
###end p 38
###begin p 39
###xml 0 91 0 91 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Both hematopoietic and nonhematopoietic cells contribute to the adjuvant effect of poly IC.</bold>
###xml 116 117 116 117 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 198 201 198 201 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 434 435 422 423 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 438 439 426 427 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 540 541 522 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 604 605 586 587 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 202 206 <span type="species:ncbi:10090">mice</span>
###xml 289 293 <span type="species:ncbi:10090">mice</span>
###xml 414 417 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Both hematopoietic and nonhematopoietic cells contribute to the adjuvant effect of poly IC. (A) Gag p24-specific CD4+ T cell responses were evaluated in bone marrow chimeras. WT and double TLR3.mda5-/- mice were lethally irradiated and injected with bone marrow cells from WT or deficient mice. After 6 wk, chimeras were primed and boosted 4 wk apart with 5 microg alpha-DEC-p24 and 50 microg poly IC. After 1 wk, HIV gag-specific CD3+CD4+ splenic T cells were analyzed for IFN-gamma secretion. Means +/- SD from two experiments are shown; n = 6. (B) Chimerism was assessed by expression of mda5 on CD11c+ splenic cells. ***, P = 0.001.
###end p 39
###begin title 40
DISCUSSION
###end title 40
###begin title 41
Poly IC as a clinically feasible adjuvant for protein-based vaccines
###end title 41
###begin p 42
###xml 613 638 613 638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib80">Trumpfheller et al., 2008</xref>
###xml 823 840 823 840 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib45">Lore et al., 2003</xref>
###xml 842 865 842 865 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib56">Napolitani et al., 2005</xref>
###xml 867 888 867 888 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib77">Thompson et al., 2005</xref>
###xml 890 905 890 905 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib24">He et al., 2007</xref>
###xml 907 929 907 929 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib50">Mata-Haro et al., 2007</xref>
###xml 465 468 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Vaccines, particularly those that elicit protective T cell immunity, are comprised of antigens and adjuvants, with the latter influencing the quantity and quality of the specific immune response. Vaccine science can be extended by understanding the mechanism of adjuvant action, particularly in the setting of the intact animal and a polyclonal T cell repertoire. In this paper, we have analyzed the adjuvant mechanism of poly IC in an experimental system in which HIV gag is the antigen and the elicited immune response is durable, broad (many peptides recognized), and capable of providing protective immunity (Trumpfheller et al., 2008). In contrast to the findings in the current paper, many prior studies of adjuvants, like CpG and LPS, have analyzed isolated cells and the clonal expansion of TCR transgenic T cells (Lore et al., 2003; Napolitani et al., 2005; Thompson et al., 2005; He et al., 2007; Mata-Haro et al., 2007).
###end p 42
###begin p 43
###xml 171 192 171 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib66">Robinson et al., 1976</xref>
###xml 311 337 311 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib75">Stahl-Hennig et al. (2009)</xref>
###xml 627 628 627 628 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 94 100 <span type="species:ncbi:9606">humans</span>
###xml 132 140 <span type="species:ncbi:9606">patients</span>
###xml 445 460 <span type="species:ncbi:9544">rhesus macaques</span>
Our interest in poly IC was initially based on two sets of findings. Poly IC has been used in humans to induce type I IFN in cancer patients and had a good safety record (Robinson et al., 1976). These studies were directed purely to the innate IFN response, rather than adjuvanting adaptive Th1 immunity. Also, Stahl-Hennig et al. (2009) have shown that poly IC is a more potent adjuvant than other agonists for responses to protein antigens in rhesus macaques. We find that poly IC is superior to several other candidate adjuvants and have identified important mechanistic aspects. For example, although both monocytes and DEC+ DCs are able to make type I IFN in response to poly IC, we found in bone marrow chimera experiments that the main source of type I IFN in vivo after administration of poly IC emanates from nonhematopoietic radioresistant cells. We proceeded to analyze the contribution of the type I IFN response to adjuvant action.
###end p 43
###begin title 44
Type I IFN but not type II or IL-12 p40 mediates the adjuvant action of poly IC
###end title 44
###begin p 45
###xml 90 107 90 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib33">Kool et al., 2008</xref>
###xml 109 124 109 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib41">Li et al., 2008</xref>
###xml 223 224 223 224 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 343 344 343 344 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 369 370 369 370 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 783 799 779 795 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib79">Trinchieri, 1994</xref>
###xml 927 948 919 940 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib42">Lighvani et al., 2001</xref>
###xml 950 971 942 963 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib1">Afkarian et al., 2002</xref>
###xml 1093 1094 1081 1082 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
A recognized feature of adjuvants is the induction of inflammatory cytokines through PRR (Kool et al., 2008; Li et al., 2008). We find that one type of cytokine, type I IFN, dominated the adjuvant role of poly IC during CD4+ Th1 immunity in vivo. Although type I IFN has been proposed to have a role during clonal expansion and survival of CD8+ T cells, its role in CD4+ Th1 development was unclear (see Introduction). However, prior experiments were done in vitro with recombinant cytokines and using CD3 antibody stimulation or transgenic models, making it difficult to extrapolate in vivo. We did consider the possibility that type I IFN could act indirectly by promoting secretion of other Th1-enhancing cytokines, IL-12 and IFN-gamma. IL-12 plays a crucial role in Th1 priming (Trinchieri, 1994), whereas IFN-gamma increases responsiveness to IL-12 and, in addition, activates the Th1-specific transcription factor T-bet (Lighvani et al., 2001; Afkarian et al., 2002). Nevertheless, our findings in vivo show that deletion of IL-12 p40 or IFN-gamma receptor genes did not abrogate the CD4+ T cell response to a protein plus poly IC vaccine, which predominantly depends on type I IFN to be an adjuvant.
###end p 45
###begin p 46
###xml 203 226 203 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib20">Gazzinelli et al., 1994</xref>
###xml 228 247 228 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib13">Cooper et al., 1997</xref>
###xml 330 349 330 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib47">Magram et al., 1996</xref>
###xml 351 369 351 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib73">Smith et al., 1999</xref>
###xml 371 392 371 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib62">Puggioni et al., 2005</xref>
###xml 394 413 394 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib26">Iborra et al., 2008</xref>
###xml 591 611 591 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib71">Schijns et al., 1998</xref>
###xml 613 633 613 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib59">Oxenius et al., 1999</xref>
###xml 824 847 824 847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib56">Napolitani et al., 2005</xref>
###xml 453 487 <span type="species:ncbi:11623">lymphocytic choriomeningitis virus</span>
###xml 492 513 <span type="species:ncbi:11138">mouse hepatitis virus</span>
The relevance of IL-12 in vivo seems to depend on the nature of the infecting or immunizing agent. IL-12 is a major cofactor for Th1 differentiation during infection with several bacteria and parasites (Gazzinelli et al., 1994; Cooper et al., 1997) as well as soluble antigens together with adjuvant, e.g., MPLA, Quil A, and CpG (Magram et al., 1996; Smith et al., 1999; Puggioni et al., 2005; Iborra et al., 2008). Yet for some virus infections, e.g., lymphocytic choriomeningitis virus and mouse hepatitis virus, the lack of IL-12 has little or no effect on the induction of Th1 immunity (Schijns et al., 1998; Oxenius et al., 1999). One criterion for the selection of a suitable Th1 adjuvant has been the production of IL-12 by DCs in vitro, in particular, when searching for synergistic effects of multiple TLR ligands (Napolitani et al., 2005). In contrast, we could not detect systemic production of IL-12 p70 after administration of poly IC, whereas poly IC was superior at inducing systemic type I IFNs. Our findings indicate that poly IC mimics infections with certain viruses, rather than bacteria and parasites, and does not require the presence of IL-12 for the induction of Th1 immunity.
###end p 46
###begin title 47
Type I IFN activates NK cells to produce type II IFN in vivo, but the latter is not required for the adjuvant action of poly IC
###end title 47
###begin p 48
###xml 271 299 267 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib49">Martin-Fontecha et al., 2004</xref>
###xml 301 322 297 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib12">Gr&#233;goire et al., 2008</xref>
###xml 451 469 447 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib68">Salem et al., 2006</xref>
###xml 654 673 646 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib83">Vitale et al., 2005</xref>
###xml 867 888 859 880 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib16">Ferlazzo et al., 2001</xref>
###xml 1117 1137 1094 1114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib58">Okamura et al., 1995</xref>
###xml 1139 1161 1116 1138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib87">Yoshimoto et al., 1998</xref>
###xml 1163 1184 1140 1161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib15">Fehniger et al., 1999</xref>
###xml 1186 1202 1163 1179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib31">Kim et al., 2000</xref>
###xml 1204 1223 1181 1200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib10">Chakir et al., 2001</xref>
###xml 1469 1492 1442 1465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib51">Matikainen et al., 2001</xref>
###xml 1531 1532 1500 1501 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1585 1589 <span type="species:ncbi:10090">mice</span>
Another major pathway to Th1 immunity involves NK cells. NK cells are rapidly recruited to lymph nodes and splenic white pulp upon stimulation with mature DCs or some adjuvants like R-848 and poly IC, providing an early source of IFN-gamma required for Th1 polarization (Martin-Fontecha et al., 2004; Gregoire et al., 2008). In addition, the production of proinflammatory cytokines by NK cells has been associated with the adjuvant effect of poly IC (Salem et al., 2006). Specifically, engagement of NKp30 by DC induces secretion of proinflammatory cytokines by NK cells, e.g., TNF-alpha, which has been identified as an active inducer of DC maturation (Vitale et al., 2005). NK cells may have additional roles in inducing DC maturation, e.g., by direct cell contact and by selective killing of mature DCs that do not express optimal levels of MHC class I molecules (Ferlazzo et al., 2001). Several inflammatory cytokines stimulate NK cell proliferation and IFN-gamma production. For example, IL-12 synergizes with IL-18 or IL-15 to induce IFN-gamma, whereas IFN-alphabeta promotes NK proliferation and cytotoxicity (Okamura et al., 1995; Yoshimoto et al., 1998; Fehniger et al., 1999; Kim et al., 2000; Chakir et al., 2001). In this paper, we have found that poly IC induces strong IFN-gamma production by NK cells and that this is fully dependent on the production of type I IFN in vivo by direct NK stimulation or though synergism with other cytokines, i.e., IL-18 (Matikainen et al., 2001). Yet IFN-gamma was not needed for CD4+ Th1 responses or DC maturation, which was normal in mice genetically lacking IFN-gamma receptor. It remains possible that NK cells serve other roles in the adjuvant effects of poly IC, i.e., independent of type II IFN.
###end p 48
###begin title 49
Innate type I IFNs in vivo induce DCs to stimulate adaptive immunity
###end title 49
###begin p 50
###xml 755 773 751 769 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib18">Fujii et al., 2003</xref>
###xml 874 894 870 890 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib23">Hawiger et al., 2001</xref>
###xml 896 916 892 912 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib8">Bonifaz et al., 2002</xref>
###xml 918 941 914 937 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib34">Kretschmer et al., 2006</xref>
###xml 943 964 939 960 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib86">Yamazaki et al., 2008</xref>
###xml 1191 1211 1187 1207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib40">Le Bon et al. (2001)</xref>
###xml 385 388 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The major challenge to understanding adjuvant function in vivo is, by definition, to understand the induction of adaptive immunity and how an early innate response to an adjuvant leads to adaptive immunity. Immunity induced by vaccination requires two broad functions at the level of DCs but needs to be studied in vivo. One is antigen presentation, which we enhanced by targeting the HIV gag protein to the DEC-205 antigen uptake receptor on a subset of DCs. Nevertheless, our mechanistic findings were similar when we administered higher doses of the antigen as an isolated gag p41 protein. The second function is that antigen-capturing DCs need to mature in vivo to induce immunity, as shown initially with another adjuvant, alpha-galactosyl ceramide (Fujii et al., 2003). Additionally, maturation is required to avoid T cell tolerance upon targeting of antigens to DCs (Hawiger et al., 2001; Bonifaz et al., 2002; Kretschmer et al., 2006; Yamazaki et al., 2008). Our experiments show that type I IFN is important for DC maturation after poly IC. Poly IC and type I IFNs were each known to induce DC maturation, but their interdependence had not previously been tested in vivo. Likewise, Le Bon et al. (2001) found that type I IFNs could act on ex vivo-derived DCs, which then stimulates antibody immunity. We noted that poly IC not only up-regulates DC costimulatory molecules but allows DCs to become better inducers of MLR. The latter assay remains valuable to document that DCs have matured in the critical functional sense and not only by altering their cell surface phenotype. Both changes in DCs, i.e., up-regulation of CD86 and increased MLR stimulation, were abrogated by blockade of type I IFN receptors. Although ligation of PRRs has previously been associated with some features of DC maturation, we showed that this is not sufficient by itself and, additionally, the development of immunostimulatory function requires direct IFNAR signaling of the DCs.
###end p 50
###begin title 51
Both bone marrow-derived and nonhematopoietic cells need to respond to poly IC
###end title 51
###begin p 52
###xml 175 204 175 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib74">Sp&#246;rri and Reis e Sousa, 2005</xref>
###xml 206 224 206 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib57">Nolte et al., 2007</xref>
###xml 402 403 402 403 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 658 676 658 676 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib53">Merad et al., 2002</xref>
###xml 1049 1050 1049 1050 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1639 1660 1639 1660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib19">Gallucci et al., 1999</xref>
###xml 1681 1700 1681 1700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib40">Le Bon et al., 2001</xref>
###xml 1726 1749 1726 1749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib17">Ferrantini et al., 1994</xref>
###xml 253 257 <span type="species:ncbi:10090">mice</span>
Elegant studies have shown that antigen-presenting cells must themselves respond to TLR agonists to induce strong clonal expansion of antigen-specific TCR transgenic T cells (Sporri and Reis e Sousa, 2005; Nolte et al., 2007), but the response of naive mice and the contribution of radioresistant cells was not fully evaluated. Unexpectedly, we found that the adjuvant role of poly IC for a primary CD4+ T cell response was severely reduced when either bone marrow-derived or radioresistant cells lacked the mda-5 and TLR3 PRRs. Radioresistant cells could include endothelial, epithelial, and stromal cells. The Langerhans type of DC is also radioresistant (Merad et al., 2002), but we found that depletion of these cells did not alter the levels of type I IFN detected in the serum. In contrast, we showed that stromal cells in vitro produced type I IFN as effectively as DCs upon poly IC stimulation, and in ongoing experiments, we find that poly IC markedly increases type I IFN mRNA in liver and lung cells suspensions that are depleted of CD11c+ cells. These findings indicate that adjuvants become more effective when they induce a systemic inflammatory response during the time that the antigen is captured and presented by DCs. In experiments that were not published, we found that the Th1 response was reduced if the administration of poly IC either preceded or followed the administration of protein antigen by 6 h. The systemic production of type I IFNs enhances two key innate responses in vivo: the maturation of DCs and the activation of NK cells, as well as key adaptive lymphocytes mediating delayed type hypersensitivity (Gallucci et al., 1999), humoral immunity (Le Bon et al., 2001), and CD8 T cell memory (Ferrantini et al., 1994). The further development of adjuvants may well need to consider the contributions of both hematopoietic and nonhematopoietic cells, which make innate cytokines that work directly on DCs so that they can act as initiators of antigen-specific adaptive immunity.
###end p 52
###begin title 53
MATERIALS AND METHODS
###end title 53
###begin title 54

###end title 54
###begin title 55
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice.
###end title 55
###begin p 56
###xml 27 28 27 28 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 74 77 70 73 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 92 95 88 91 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 144 147 140 143 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 209 212 205 208 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 297 300 293 296 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 361 365 <span type="species:ncbi:10090">Mice</span>
C57BL/6, BALB/c, and CxB6 F1 were obtained from Harlan, 129/SvJ, IFNgammaR-/-, and IL-12 p40-/- were obtained from The Jackson Laboratory, STAT1-/- were provided by D. Levy (New York University, NY, NY), IFNAR-/- were provided by K. Murali-Krishna (University of Washington, Seattle, WA), and TLR3-/- were provided by S. Akira (Osaka University, Osaka, Japan). Mice were maintained under specific pathogen-free conditions and used at 7-8 wk of age according to Institutional Animal Care and Use guidelines. Animal protocols were approved by the Institutional Animal Care and Use Committee (IACUC).
###end p 56
###begin title 57
In vivo cytokine secretion.
###end title 57
###begin p 58
###xml 145 152 129 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E. Coli</italic>
###xml 299 300 263 264 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice were injected i.p. with 50 microg poly IC (InvivoGen), 50 microg Pam3cys (InvivoGen), 0.5 microg Malp2 (Enzo Biochem, Inc.), 10 microg LPS (E. Coli; Sigma-Aldrich), 50 microg poly ICLC (Oncovir, Inc.), 50 microg CpG ODN1826 (InvivoGen), or R-848 cream (2% topically applied to approximately5 cm2 of back skin; Celldex Therapeutics, Inc.), and serum was collected at the indicated times. Production of TNF-alpha, IL-12p40, IL-12p70, IL-6, IFN-gamma (eBioscience), and IFN-alpha and IFN-beta (R&D Systems) was determined by ELISA according to the manufacturer's instructions.
###end p 58
###begin title 59
Cell sorting and stromal cell isolation.
###end title 59
###begin p 60
###xml 128 129 122 123 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sc>
###xml 999 1017 993 1011 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib11">Cheng et al., 2007</xref>
Spleens were cut in small pieces and incubated at 37degreesC for 30 min in Hank's medium supplemented with 400 U/ml collagenase d (Roche). EDTA (5 mM in final concentration) was added for the last 5 min. Cells were stained with biotinylated anti-CD3, anti-CD19, and anti-Ter119 mAbs (BD) for 20 min, washed, incubated with Streptavidin-coated magnetic beads, and passed through LD columns (Miltenyi Biotec). The negative fraction was collected and stained with Live/Dead Fixable Aqua viability dye (Invitrogen), FITC-anti-DX5, PE-anti-CD11c, PercPCy5.5-B220, Pacific Blue-anti-CD3, Alexa Fluor 750-anti-CD8 (eBioscience), and Alexa Fluor 647-DEC-205 (produced in house). Alternatively, cells were stained with Fixable Aqua viability dye, FITC-anti-Ly6G, PE-anti-CD115, PerCP-anti-F4/80, PE-Cy7-anti-CD11c, and Alexa Fluor 750-CD11b (eBioscience). Different populations were isolated by sorting on a FACSAria with DiVa configuration (BD). Splenic stromal cells were obtained as previously described (Cheng et al., 2007). In brief, spleens were cut into small fragments, placed in a 48MW plate, and cultured in RPMI 1640 medium supplemented with 20% FCS and 1% MEM nonessential amino acids. After 1 mo, cells were further purified by CD45 negative selection.
###end p 60
###begin title 61
ELISA for antibody response.
###end title 61
###begin p 62
###xml 380 384 <span type="species:ncbi:9925">goat</span>
###xml 390 395 <span type="species:ncbi:10090">mouse</span>
To detect gag-specific antibody, high-binding ELISA plates (BD) were coated with 1 microg/ml of gag protein overnight at 4degreesC, washed with PBS/0.1% Tween 20, and blocked with PBS/5% BSA for 1 h at 37degreesC. Serial dilutions of serum were added to the plates and incubated for another 1 h at 37degreesC. Plates were washed and incubated 1 h at 37degreesC with secondary HRP goat anti-mouse IgG antibody (Jackson Immunoresearch Laboratories). TMB (3,3',5,5-tetramethylbenzidine) substrate solution (Thermo Fisher Scientific) was used as substrate. OD was measured in an ELISA reader at 450 nm.
###end p 62
###begin title 63
DC maturation and function.
###end title 63
###begin p 64
###xml 321 323 313 315 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hi</sup>
###xml 326 327 318 319 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 336 338 328 330 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hi</sup>
###xml 341 342 333 334 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 450 452 442 444 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hi</sup>
###xml 458 459 450 451 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 466 469 458 461 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 479 481 471 473 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hi</sup>
###xml 487 488 479 480 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 539 540 531 532 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 872 873 864 865 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 377 381 <span type="species:ncbi:10090">mice</span>
###xml 683 687 <span type="species:ncbi:10090">mice</span>
Mice were injected i.p. with 100 microg of anti-IFNAR blocking antibody or isotype control (Leinco Technologies) and 1 h later with PBS or 50 microg poly IC. Spleens were collected 12 h later and collagenase digested. Maturation was monitored by increased expression of MHC-II (I-Ek), CD86, and CD40 after gating on CD11chiDEC- or CD11chiDEC+ DCs. In mixed bone marrow chimera mice, expression of maturation markers was analyzed after gating on CD11chiCD45.2+ (IFNAR-/-) or CD11chiCD45.2- DCs. To test DC stimulatory capacity, spleen CD11c+ DCs were isolated 12 h after administration of poly IC with anti-IFNAR blocking antibody or isotype control. Alternatively, for mixed chimera mice, WT and IFNAR-deficient DCs were FACS sorted based on the expression of CD45.2. BALB/c DCs were fixed with 1% paraformaldehyde for 10 min on ice and graded numbers were added to 2 x 105 CFSE-labeled (Invitrogen) C57BL/6 T cells. After 5 d of culture, samples were stained with Live/Dead Fixable Aqua viability dye and Pacific blue-anti-CD3 and acquired on an LSR II flow cytometer (BD).
###end p 64
###begin title 65
NK activation.
###end title 65
###begin p 66
###xml 369 370 357 358 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 373 374 361 362 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 397 398 385 386 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
2 h after 50 microg poly IC i.p., spleen cell suspensions were prepared and incubated for 3 h with 10 microg/ml brefeldin A (Sigma-Aldrich). Cells were stained with Live/Dead Fixable Aqua viability dye, FITC-anti-DX5, PE-anti-CD11c, and Pacific Blue-anti-CD3 mAbs. Cells were then fixed, permeabilized, and stained with APC-anti-IFN-gamma antibody. Sorted NK cells (CD3-DX5+) were cultured (3 x 105) with 50 microg/ml poly IC or 2 ng/ml rIL-12 and 1 ng/ml rIL-15 (eBioscience).
###end p 66
###begin title 67
Bone marrow chimeras.
###end title 67
###begin p 68
###xml 114 115 110 111 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 271 272 267 268 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 10 14 <span type="species:ncbi:10090">mice</span>
###xml 195 199 <span type="species:ncbi:10090">mice</span>
###xml 213 217 <span type="species:ncbi:10090">mice</span>
Recipient mice were gamma irradiated twice with 500 rad, 3 h apart. 3 h later, they were reconstituted with 3 x 106 marrow cells that had been harvested from the femurs and tibias of age-matched mice. After 6 wk, mice were tested for chimerism by RT-PCR for mda5 on CD11c+ cells (InvivoGen) or by flow cytometry, based on the expression of CD45.1 and CD45.2 (>98%).
###end p 68
###begin title 69
###xml 27 28 27 28 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 11 14 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Assays for HIV-specific CD4+ T cells.
###end title 69
###begin p 70
###xml 102 127 94 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib80">Trumpfheller et al., 2008</xref>
###xml 284 285 256 257 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 63 66 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 89 92 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 334 338 <span type="species:ncbi:10090">mice</span>
Mice were immunized twice i.p. at 4-wk intervals with 5 microg HIV gag-p24 and 10 microg HIV gag-p41 (Trumpfheller et al., 2008) together with adjuvant, which was 50 microg poly IC, 50 microg Pam3cys, 0.5 microg Malp-2, 10 microg LPS, 50 microg poly ICLC, and R-848 cream (topic, 5 cm2) or 50 microg CpG ODN1826. For IFNAR1 blocking, mice were simultaneously injected days 0 and 2, with 100 microg of anti-IFNAR blocking antibody or isotype control. 1 wk later, splenocytes were restimulated with 2 microM p24 or negative control peptide mix, along with 2 microg/ml of costimulatory alpha-CD28 (clone 37.51) for 6 h. 10 microg/ml brefeldin A was added for the last 5 h. Cells were washed, incubated 10 min at 4degreesC with 2.4G2 mAb to block Fcgamma receptors, washed, and stained with Live/Dead Fixable Aqua viability dye, Pacific blue-conjugated anti-CD3, PerCP-conjugated anti-CD4, and Alexa Fluor 750-conjugated anti-CD8 mAbs for 20 min at 4degreesC. Cells were permeabilized (Cytofix/Cytoperm Plus; BD) and stained with APC-anti-IFN-gamma, PE-anti-IL-2, and PE-Cy7 anti-TNF-alpha mAbs for 15 min at room temperature (BD). Samples were acquired on an LSR II flow cytometer and analyzed with FlowJo Software (Tree Star, Inc.).
###end p 70
###begin title 71
Statistical analysis.
###end title 71
###begin p 72
###xml 68 69 68 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
Statistical significance was evaluated using a two-tailed Student's t test with a 95% confidence interval. Results are expressed as means +/- SD. In the figures, p-values of 0.001 are labeled with a triple asterisk. Analysis was performed with a Prism 3 program (GraphPad Software, Inc.).
###end p 72
###begin title 73
Online supplemental material.
###end title 73
###begin p 74
###xml 63 64 59 60 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 308 314 304 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7</xref>
Fig. S1 shows the frequency of IL-2 and TNF-alpha-producing CD4+ T cells after DEC-p24 immunization with different adjuvants. Fig. S2 demonstrates the mda-5 dependence of the production of type I IFN in serum. Fig. S3 shows the gating strategy for the MLR assays. Fig. S4 shows representative dot plots from Fig. 7.
###end p 74
###begin title 75
Supplementary Material
###end title 75
###begin title 76
[Supplemental Material]
###end title 76
###begin p 77
###xml 249 254 <span type="species:ncbi:9606">Human</span>
This research was supported by the National Institute of Allergy and Infectious Diseases (grants AI13013 and AI40874 to R.M. Steinman), by a Center for AIDS Vaccine Discovery grant from the Bill and Melinda Gates Foundation, and by a grant from the Human Frontiers of Science Program.
###end p 77
###begin p 78
###xml 116 122 <span type="species:ncbi:9606">humans</span>
R.M. Steinman is a scientific advisor to Celldex Therapeutics, which is developing DEC-targeted vaccines for use in humans. A.M. Salazar heads Oncovir, which produces poly ICLC. The authors have no additional financial interest.
###end p 78
###begin article-title 79
###xml 68 69 68 69 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
T-bet is a STAT1-induced regulator of IL-12R expression in naive CD4+ T cells.
###end article-title 79
###begin article-title 80
Pathogen recognition and innate immunity.
###end article-title 80
###begin article-title 81
Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3.
###end article-title 81
###begin article-title 82
Type I interferon dependence of plasmacytoid dendritic cell activation and migration.
###end article-title 82
###begin article-title 83
###xml 105 111 <span type="species:ncbi:10090">murine</span>
Frontline: absence of functional STAT4 activation despite detectable tyrosine phosphorylation induced by murine IFN-alpha.
###end article-title 83
###begin article-title 84
Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus.
###end article-title 84
###begin article-title 85
###xml 39 40 39 40 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 45 46 45 46 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 51 52 51 52 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 28 34 <span type="species:ncbi:10090">murine</span>
Development and function of murine B220+CD11c+NK1.1+ cells identify them as a subset of NK cells.
###end article-title 85
###begin article-title 86
###xml 199 200 199 200 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance.
###end article-title 86
###begin article-title 87
###xml 80 81 72 73 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 71 76 <span type="species:ncbi:9606">human</span>
Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T cells.
###end article-title 87
###begin article-title 88
###xml 33 34 33 34 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 23 29 <span type="species:ncbi:10090">murine</span>
Cytokine expression by murine DX5+ cells in response to IL-12, IL-18, or the combination of IL-12 and IL-18.
###end article-title 88
###begin article-title 89
Regulation of dendritic-cell differentiation by bone marrow stroma via different Notch ligands.
###end article-title 89
###begin article-title 90
###xml 112 138 112 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Mycobacterium tuberculosis</italic>
###xml 79 83 <span type="species:ncbi:10090">mice</span>
###xml 112 138 <span type="species:ncbi:1773">Mycobacterium tuberculosis</span>
Interleukin 12 (IL-12) is crucial to the development of protective immunity in mice intravenously infected with Mycobacterium tuberculosis.
###end article-title 90
###begin article-title 91
###xml 58 65 58 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
Differential antigen processing by dendritic cell subsets in vivo.
###end article-title 91
###begin article-title 92
###xml 55 60 <span type="species:ncbi:9606">human</span>
Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response.
###end article-title 92
###begin article-title 93
HLA class I molecule expression is up-regulated during maturation of dendritic cells, protecting them from natural killer cell-mediated lysis.
###end article-title 93
###begin article-title 94
###xml 88 89 84 85 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 45 51 <span type="species:ncbi:10090">murine</span>
IFN-alpha1 gene expression into a metastatic murine adenocarcinoma (TS/A) results in CD8+ T cell-mediated tumor rejection and development of antitumor immunity. Comparative studies with IFN-gamma-producing TS/A cells.
###end article-title 94
###begin article-title 95
Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a co-administered protein.
###end article-title 95
###begin article-title 96
Natural adjuvants: endogenous activators of dendritic cells.
###end article-title 96
###begin article-title 97
###xml 103 120 99 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Toxoplasma gondii</italic>
###xml 103 120 <span type="species:ncbi:5811">Toxoplasma gondii</span>
Parasite-induced IL-12 stimulates early IFN-gamma synthesis and resistance during acute infection with Toxoplasma gondii.
###end article-title 97
###begin article-title 98
Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus.
###end article-title 98
###begin article-title 99
Intrasplenic trafficking of natural killer cells is redirected by chemokines upon inflammation.
###end article-title 99
###begin article-title 100
Cutting edge: the direct action of type I IFN on CD4 T cells is critical for sustaining clonal expansion in response to a viral but not a bacterial infection.
###end article-title 100
###begin article-title 101
Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo.
###end article-title 101
###begin article-title 102
###xml 27 32 <span type="species:ncbi:9606">human</span>
Antigenic targeting of the human mannose receptor induces tumor immunity.
###end article-title 102
###begin article-title 103
Selective contribution of IFN-alpha/beta signaling to the maturation of dendritic cells induced by double-stranded RNA or viral infection.
###end article-title 103
###begin article-title 104
###xml 21 37 21 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Leishmania major</italic>
###xml 21 37 <span type="species:ncbi:5664">Leishmania major</span>
###xml 155 159 <span type="species:ncbi:10090">mice</span>
Vaccination with the Leishmania major ribosomal proteins plus CpG oligodeoxynucleotides induces protection against experimental cutaneous leishmaniasis in mice.
###end article-title 104
###begin article-title 105
###xml 27 32 <span type="species:ncbi:9606">human</span>
Differential regulation of human blood dendritic cell subsets by IFNs.
###end article-title 105
###begin article-title 106
Cell type-specific involvement of RIG-I in antiviral response.
###end article-title 106
###begin article-title 107
Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses.
###end article-title 107
###begin article-title 108
The roles of TLRs, RLRs and NLRs in pathogen recognition.
###end article-title 108
###begin article-title 109
###xml 81 85 <span type="species:ncbi:10090">mice</span>
In vivo natural killer cell activities revealed by natural killer cell-deficient mice.
###end article-title 109
###begin article-title 110
Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection.
###end article-title 110
###begin article-title 111
Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells.
###end article-title 111
###begin article-title 112
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">De novo</italic>
###xml 56 63 56 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
De novo production of antigen-specific suppressor cells in vivo.
###end article-title 112
###begin article-title 113
Alveolar macrophages are the primary interferon-alpha producer in pulmonary infection with RNA viruses.
###end article-title 113
###begin article-title 114
The science of adjuvants.
###end article-title 114
###begin article-title 115
###xml 52 57 <span type="species:ncbi:9606">human</span>
The direct effects of Toll-like receptor ligands on human NK cell cytokine production and cytotoxicity.
###end article-title 115
###begin article-title 116
###xml 60 61 60 61 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Direct stimulation of T cells by type I IFN enhances the CD8+ T cell response during cross-priming.
###end article-title 116
###begin article-title 117
Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo.
###end article-title 117
###begin article-title 118
###xml 20 21 20 21 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon.
###end article-title 118
###begin article-title 119
Inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3.
###end article-title 119
###begin article-title 120
T-bet is rapidly induced by interferon-gamma in lymphoid and myeloid cells.
###end article-title 120
###begin article-title 121
Studies on the production, mode of action and properties of interferon.
###end article-title 121
###begin article-title 122
TLR-independent induction of dendritic cell maturation and adaptive immunity by negative-strand RNA viruses.
###end article-title 122
###begin article-title 123
###xml 84 89 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus- and HIV-1-specific T cell responses.
###end article-title 123
###begin article-title 124
Type I IFNs enhance the terminal differentiation of dendritic cells.
###end article-title 124
###begin article-title 125
###xml 16 20 <span type="species:ncbi:10090">mice</span>
IL-12-deficient mice are defective in IFN-gamma production and type 1 cytokine responses.
###end article-title 125
###begin article-title 126
Type I interferons keep activated T cells alive.
###end article-title 126
###begin article-title 127
###xml 71 72 67 68 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
Induced recruitment of NK cells to lymph nodes provides IFN-gamma for TH1 priming.
###end article-title 127
###begin article-title 128
The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4.
###end article-title 128
###begin article-title 129
###xml 70 75 <span type="species:ncbi:9606">human</span>
IFN-alpha; and IL-18 synergistically enhance IFN-gamma; production in human NK cells: differential regulation of Stat4 activation and IFN-gamma gene expression by IFN-alpha; and IL-12.
###end article-title 129
###begin article-title 130
Controlling the Toll road to dendritic cell polarization.
###end article-title 130
###begin article-title 131
Langerhans cells renew in the skin throughout life under steady-state conditions.
###end article-title 131
###begin article-title 132
Type I interferons produced by dendritic cells promote their phenotypic and functional activation.
###end article-title 132
###begin article-title 133
Pouvoir immunisant du virus vaccinal inactive par des rayons ultraviolets.
###end article-title 133
###begin article-title 134
Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells.
###end article-title 134
###begin article-title 135
Dendritic cell quiescence during systemic inflammation driven by LPS stimulation of radioresistant cells in vivo.
###end article-title 135
###begin article-title 136
Cloning of a new cytokine that induces IFN-gamma production by T cells.
###end article-title 136
###begin article-title 137
IL-12 is not required for induction of type 1 cytokine responses in viral infections.
###end article-title 137
###begin article-title 138
Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells.
###end article-title 138
###begin article-title 139
Expression of CCR-7, MIP-3beta, and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities.
###end article-title 139
###begin article-title 140
Monophosphoryl lipid A (MPL) promotes allergen-induced immune deviation in favour of Th1 responses.
###end article-title 140
###begin article-title 141
Translating innate immunity into immunological memory: implications for vaccine development.
###end article-title 141
###begin article-title 142
IFN-alpha is not sufficient to drive Th1 development due to lack of stable T-bet expression.
###end article-title 142
###begin article-title 143
Antigen presentation by monocytes and monocyte-derived cells.
###end article-title 143
###begin article-title 144
###xml 77 85 <span type="species:ncbi:9606">patients</span>
A phase I-II trial of multiple-dose polyriboinosic-polyribocytidylic acid in patients with leukemia or solid tumors.
###end article-title 144
###begin article-title 145
###xml 64 69 <span type="species:ncbi:9606">human</span>
Selective expression of an interleukin-12 receptor component by human T helper 1 cells.
###end article-title 145
###begin article-title 146
The adjuvant effects of the toll-like receptor 3 ligand polyinosinic-cytidylic acid poly (I:C) on antigen-specific CD8+ T cell responses are partially dependent on NK cells with the induction of a beneficial cytokine milieu.
###end article-title 146
###begin article-title 147
###xml 130 134 <span type="species:ncbi:10090">mice</span>
Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in hu-PBL-SCID mice.
###end article-title 147
###begin article-title 148
###xml 40 45 <span type="species:ncbi:10090">mouse</span>
Type 1 cytokine/chemokine production by mouse NK cells following activation of their TLR/MyD88-mediated pathways.
###end article-title 148
###begin article-title 149
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice lacking IL-12 develop polarized Th1 cells during viral infection.
###end article-title 149
###begin article-title 150
Basic immunology of vaccine development. 
###end article-title 150
###begin article-title 151
The Vaccine Book. 
###end article-title 151
###begin article-title 152
Immune-stimulating complexes induce an IL-12-dependent cascade of innate immune responses.
###end article-title 152
###begin article-title 153
###xml 103 104 103 104 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Inflammatory mediators are insufficient for full dendritic cell activation and promote expansion of CD4+ T cell populations lacking helper function.
###end article-title 153
###begin article-title 154
###xml 109 129 <span type="species:ncbi:10566">human papillomavirus</span>
###xml 133 148 <span type="species:ncbi:9544">rhesus macaques</span>
Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques.
###end article-title 154
###begin article-title 155
Macrophage receptors and immune recognition.
###end article-title 155
###begin article-title 156
The low-toxicity versions of LPS, MPL(R) adjuvant and RC529, are efficient adjuvants for CD4+ T cells.
###end article-title 156
###begin article-title 157
Induction of bystander T cell proliferation by viruses and type I interferon in vivo.
###end article-title 157
###begin article-title 158
Interleukin-12: A cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes.
###end article-title 158
###begin article-title 159
###xml 61 62 61 62 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
The microbial mimic polyIC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine.
###end article-title 159
###begin article-title 160
###xml 14 20 <span type="species:ncbi:10090">murine</span>
Maturation of murine bone marrow-derived dendritic cells with poly(I:C) produces altered TLR-9 expression and response to CpG DNA.
###end article-title 160
###begin article-title 161
Vaccine manufacturing: challenges and solutions.
###end article-title 161
###begin article-title 162
###xml 101 106 <span type="species:ncbi:9606">human</span>
Polyriboinosinic polyribocytidylic acid (poly(I:C)) induces stable maturation of functionally active human dendritic cells.
###end article-title 162
###begin article-title 163
NK-dependent DC maturation is mediated by TNFalpha and IFNgamma released upon engagement of the NKp30 triggering receptor.
###end article-title 163
###begin article-title 164
Natural-killer cells and dendritic cells: "l'union fait la force".
###end article-title 164
###begin article-title 165
Roles of IFN-gamma and IFN-alpha in IL-12-induced T helper cell-1 development.
###end article-title 165
###begin article-title 166
###xml 3 4 3 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 10 11 10 11 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 67 68 67 68 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
CD8+ CD205+ splenic dendritic cells are specialized to induce Foxp3+ regulatory T cells.
###end article-title 166
###begin article-title 167
IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-gamma production.
###end article-title 167
###begin p 168
Abbreviations used: cDC, conventional DC; poly IC, polyinosinic:polycytidylic acid; PRR, pattern recognition receptor; TLRs, Toll-like receptor.
###end p 168

